Skip to main content
. 2014 Mar 19;348:g1996. doi: 10.1136/bmj.g1996

Table 6.

 Hazard ratios (95% confidence intervals) for age adjusted associations between defined daily doses (DDDs) of study drug and mortality before and after adjusting for other potential confounders, for exposure restricted to receipt of study drugs in first year after recruitment only and for patients with at least 12 months of follow-up

DDDs No of patients Age adjusted hazard ratio (95% CI) P value Fully adjusted* hazard ratio (95% CI) P value
All study drugs:
 0 63 717 1.00 1.00
 1-30 5142 1.46 (1.35 to 1.57) <0.001 1.45 (1.35 to 1.56) <0.001
 31-60 1873 2.02 (1.82 to 2.23) <0.001 1.94 (1.76 to 2.16) <0.001
 61-90 659 2.27 (1.94 to 2.66) <0.001 1.87 (1.59 to 2.19) <0.001
 ≥91 910 3.14 (2.80 to 3.52) <0.001 2.63 (2.34 to 2.95) <0.001
Any DDDs 8584 1.83 (1.73 to 1.92) <0.001 1.75 (1.65 to 1.85) <0.001
Benzodiazepines only:
 1-30 3561 1.46 (1.33 to 1.59) <0.001 1.47 (1.34 to 1.61) <0.001
 31-60 791 2.31 (2.01 to 2.65) <0.001 2.07 (1.80 to 2.38) <0.001
 61-90 251 2.63 (2.09 to 3.32) <0.001 2.31 (1.84 to 2.92) <0.001
 ≥91 361 4.14 (3.53 to 4.87) <0.001 3.32 (2.83 to 3.89) <0.001
Any DDDs 4964 1.88 (1.76 to 2.02) <0.001 1.81 (1.68 to 1.94) <0.001
Z drugs only:
 1-30 655 1.39 (1.12 to 1.71) <0.001 1.34 (1.08 to 1.66) <0.001
 31-60 603 2.05 (1.67 to 2.51) <0.001 2.05 (1.67 to 2.51) <0.001
 61-90 186 2.43 (1.76 to 3.36) <0.001 1.81 (1.31 to 2.51) <0.001
 ≥91 271 2.7 (2.15 to 3.39) <0.001 2.25 (1.79 to 2.84) <0.001
Any DDDs 1715 1.94 (1.72 to 2.17) <0.001 1.78 (1.58 to 2.01) <0.001
Other study drugs only:
 1-30 785 1.5 (1.28 to 1.75) <0.001 1.45 (1.24 to 1.69) <0.001
 31-60 310 1.58 (1.26 to 2.01) <0.001 1.65 (1.31 to 2.09) <0.001
 61-90 113 1.93 (1.32 to 2.84) <0.001 1.75 (1.19 to 2.57) <0.001
 ≥91 109 2.36 (1.73 to 3.25) <0.001 1.9 (1.39 to 2.61) <0.001
Any DDDs 1317 1.63 (1.45 to 1.82) <0.001 1.57 (1.40 to 1.76) <0.001

*Age, sex, physical health problems (arthritis, asthma, cancer, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, diabetes, epilepsy, gastrointestinal disorders, hypertension, musculoskeletal disorders, anxiety disorders, sleep disorders), other (non-anxiety) psychiatric disorders, and prescriptions for non-study drugs.